StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $3.51 | $2.95 | -15.95% | 0.0M |
| 05-12 | $2.99 | $3.01 | +0.67% | 0.0M |
| 05-13 | $3.02 | $3.55 | +17.74% | 0.1M |
| 05-14 | $3.63 | $3.34 | -7.99% | 0.0M |
| 05-15 | $3.33 | $3.13 | -6.01% | 0.0M |
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Each factor shows NEPH's percentile within the scored universe — observational ranking, not a recommendation.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
| Metric | Q3 2026 (Est.) Expected 2026-08-05 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $4.92M | $5.21M | $18.79M | $14.06M | $9.30M |
Operating Income | Not available | $97.00K | $1.15M | $1.13M | $814.00K |
Net Income | Not available | $140.00K | $1.19M | $1.13M | $237.00K |
EPS (Diluted) | $0.00 | $0.01 | $0.11 | $0.10 | $0.07 |
Total Assets | Not available | $13.79M | $13.64M | $13.25M | $12.24M |
Total Liabilities | Not available | $3.09M | $3.44M | $3.24M | $2.64M |
Cash & Equivalents | Not available | $4.02M | $5.40M | $5.17M | $5.07M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available | Not available |
Shares Outstanding | Not available | 10.84M | 10.64M | 10.63M | 10.60M |